Significant active cardiovascular or pulmonary disease at the time of study entry, including\r\n* Uncontrolled high blood pressure (i.e., systolic blood pressure >  mm Hg, diastolic blood pressure >  mm Hg) \r\n* Pulmonary hypertension  \r\n* Uncontrolled asthma or oxygen (O) saturation < % by ABG (arterial blood gas) analysis or pulse oximetry on room air   \r\n* Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement  \r\n* Medically significant (symptomatic) bradycardia
Patients with known significant active cardiovascular or pulmonary disease at the time of study entry are INELIGIBLE including:\r\n* Uncontrolled hypertension (i.e., systolic blood pressure > mm Hg, diastolic blood pressure >  mm Hg); use of anti-hypertensive agents to control hypertension before cycle day  is allowed\r\n* Pulmonary hypertension\r\n* Uncontrolled asthma or oxygen (O) saturation < % by arterial blood gas analysis or pulse oximetry on room air\r\n* QT syndrome, or torsades de pointes\r\n* Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement\r\n* Medically significant (symptomatic) bradycardia\r\n* History of arrhythmia requiring an implantable cardiac defibrillator\r\n* Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval >  milliseconds, or history of congenital long
Significant active cardiovascular or pulmonary disease at the time of study registration, including:\r\n* Uncontrolled high blood pressure (i.e., systolic blood pressure >  mm Hg, diastolic blood pressure >  mm Hg)\r\n* Pulmonary hypertension\r\n* Uncontrolled asthma or oxygen (O) saturation < % by ABG (arterial blood gas) analysis or pulse oximetry on room air\r\n* Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement\r\n* Medically significant (symptomatic) bradycardia\r\n* History of arrhythmia requiring an implantable cardiac defibrillator\r\n* Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval >  milliseconds, or history of congenital long QT syndrome, or torsades de pointes)
Significant active cardiovascular or pulmonary disease at the time of study entry, including:\r\n* Uncontrolled high blood pressure (i.e., systolic blood pressure >  mm Hg, diastolic blood pressure >  mm Hg)\r\n* Pulmonary hypertension\r\n* Uncontrolled asthma or oxygen (O) saturation < % by arterial blood gas (ABG) analysis or pulse oximetry on room air\r\n* Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement\r\n* Medically significant (symptomatic) bradycardia\r\n* History of arrhythmia requiring an implantable cardiac defibrillator\r\n* Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval >  milliseconds, or history of congenital long QT syndrome, or torsades de pointes)
Significant active cardiovascular or pulmonary disease including: a) Uncontrolled hypertension (i.e., systolic blood pressure > mm Hg, diastolic blood pressure >  mm Hg). Use of anti-hypertensive agents to control hypertension before cycle day  is allowed. b) Pulmonary hypertension c) Uncontrolled asthma or oxygen (O) saturation < % by arterial blood gas analysis or pulse oximetry on room air d) Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement e) Medically significant (symptomatic) bradycardia f) History of arrhythmia requiring an implantable cardiac defibrillator g) Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval >  milliseconds, or history of congenital long QT syndrome, or torsades de pointes).
Significant active cardiovascular or pulmonary disease at the time of study entry, including: uncontrolled high blood pressure (i.e., systolic blood pressure >  mm Hg, diastolic blood pressure >  mm Hg); use of anti-hypertensive agents to control hypertension before cycle  day  is allowed; pulmonary hypertension; uncontrolled asthma or oxygen (O) saturation < % by ABG (arterial blood gas) analysis or pulse oximetry on room air; significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement; medically significant (symptomatic) bradycardia; history of arrhythmia requiring an implantable cardiac defibrillator; baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval >  milliseconds, or history of congenital long QT syndrome, or torsades de pointes)
Significant active cardiovascular or pulmonary disease including:\r\n* Uncontrolled hypertension (i.e., systolic blood pressure >  mm Hg, diastolic blood pressure >  mm Hg); use of anti-hypertensive agents to control hypertension before cycle  day  is allowed\r\n* Pulmonary hypertension\r\n* Uncontrolled asthma or oxygen (O) saturation < % by arterial blood gas analysis or pulse oximetry on room air\r\n* Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement\r\n* Medically significant (symptomatic) bradycardia\r\n* History of arrhythmia requiring an implantable cardiac defibrillator\r\n* Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval >  milliseconds, or history of congenital long QT syndrome, or torsades de pointes)
Significant active cardiovascular or pulmonary disease at the time of study entry, including: uncontrolled high blood pressure (i.e., systolic blood pressure > mm Hg, diastolic blood pressure >  mm Hg); use of anti-hypertensive agents to control hypertension before cycle  day  is allowed; pulmonary hypertension; uncontrolled asthma or oxygen (O) saturation < % by ABG (arterial blood gas) analysis or pulse oximetry on room air; significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement; medically significant (symptomatic) bradycardia; history of arrhythmia requiring an implantable cardiac defibrillator; baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval >  milliseconds, or history of congenital long QT syndrome, or torsades de pointes)
Significant active cardiovascular or pulmonary disease including:\r\n* Uncontrolled hypertension (i.e., systolic blood pressure >  mm Hg, diastolic blood pressure >  mm Hg); use of anti-hypertensive agents to control hypertension before cycle day  is allowed\r\n* Pulmonary hypertension\r\n* Uncontrolled asthma or oxygen (O) saturation < % by arterial blood gas analysis or pulse oximetry on room air\r\n* Significant valvular disease; severe regurgitation or stenosis by imaging\r\nindependent of symptom control with medical intervention, or history of valve\r\nreplacement\r\n* Medically significant (symptomatic) bradycardia\r\n* History of arrhythmia requiring an implantable cardiac defibrillator\r\n* Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval >  milliseconds, or history of congenital long QT syndrome, or torsades de pointes)
Significant active cardiovascular or pulmonary disease at the time of study entry, including:\r\n* Uncontrolled high blood pressure (i.e., systolic blood pressure >  mm Hg, diastolic blood pressure >  mm Hg)\r\n* Pulmonary hypertension\r\n* Uncontrolled asthma or oxygen (O) saturation < % by ABG (arterial blood gas) analysis or pulse oximetry on room air\r\n* Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement\r\n* Medically significant (symptomatic) bradycardia\r\n* History of arrhythmia requiring an implantable cardiac defibrillator\r\n* Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval >  milliseconds, or history of congenital long QT syndrome, or torsade de pointes)
Significant active cardiovascular or pulmonary disease at the time of study entry, including:\r\n* Uncontrolled high blood pressure (i.e., systolic blood pressure >  mm Hg, diastolic blood pressure >  mm Hg)\r\n* Pulmonary hypertension\r\n* Uncontrolled asthma or oxygen (O) saturation < % by pulse oximetry on room air\r\n* Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement\r\n* Medically significant (symptomatic) bradycardia\r\n* History of arrhythmia requiring an implantable cardiac defibrillator
Significant active cardiovascular or pulmonary disease at the time of study entry,\r\nincluding:\r\n* Uncontrolled high blood pressure (i.e., systolic blood pressure >  mm Hg, diastolic blood pressure >  mm Hg)\r\n* Pulmonary hypertension\r\n* Uncontrolled asthma or oxygen (O) saturation < % by ABG (arterial blood gas) analysis or pulse oximetry on room air\r\n* Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement\r\n* Medically significant (symptomatic) bradycardia\r\n* History of arrhythmia requiring an implantable cardiac defibrillator\r\n* Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval >  milliseconds, or history of congenital long QT syndrome, or torsades de pointes)
Significant active cardiovascular or pulmonary disease including:\r\n* Uncontrolled hypertension (i.e., systolic blood pressure >  mm Hg, diastolic blood pressure >  mm Hg); use of anti-hypertensive agents to control hypertension before cycle day  is allowed,\r\n* Pulmonary hypertension,\r\n* Uncontrolled asthma or oxygen (O) saturation < % by arterial blood gas analysis or pulse oximetry on room air,\r\n* Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement,\r\n* Medically significant (symptomatic) bradycardia,\r\n* History of arrhythmia requiring an implantable cardiac defibrillator,\r\n* Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval >  milliseconds, or history of congenital long QT syndrome, or torsades de pointes)